找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Immunotherapy of Melanoma; Anand Rotte,Madhuri Bhandaru Book 2016 Springer International Publishing AG 2016 Melanoma.Immunotherapy.Check p

[复制链接]
楼主: 欺骗某人
发表于 2025-3-25 04:13:31 | 显示全部楼层
发表于 2025-3-25 11:01:52 | 显示全部楼层
发表于 2025-3-25 11:45:35 | 显示全部楼层
Dendritic Cells and class II pathways as well as the CD1 pathway and the significance of costimulation in the activation of T-cells are described. Role of DCs and the DC-secreted cytokines in induction of T-cell differentiation into different types of effector T-cells are discussed. The interaction between DCs and
发表于 2025-3-25 18:21:15 | 显示全部楼层
发表于 2025-3-25 21:55:32 | 显示全部楼层
发表于 2025-3-26 00:48:06 | 显示全部楼层
Interferon-α2bogy as well as pharmacology of IFN-α2b. The chapter begins with few historical details related to IFN discovery, then lists the different types of IFN families (Type I, II and III) and their respective receptors, describes the structure and SAR of IFN-α2b and discusses the details of IFNAR signal tr
发表于 2025-3-26 07:44:42 | 显示全部楼层
发表于 2025-3-26 12:00:13 | 显示全部楼层
Ipilimumabt, the description of marketed ipilimumab formulation (Yervoy) is given along with the details of its clinical pharmacology. The mechanism of action of ipilimumab is then described followed by discussion on results from clinical trials that demonstrated the benefits of ipilimumab in treatment of pat
发表于 2025-3-26 16:25:26 | 显示全部楼层
Nivolumabcient mice (.. mice) are described. Next, the structure of PD-1 receptor, its biology and the signaling events that follow the activation of PD-1 receptor are explained. After giving a brief description of Opdivo, the marketed formulation of nivolumab, its clinical pharmacology and mechanism of acti
发表于 2025-3-26 19:50:43 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-17 02:00
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表